A Harvard professor’s cell therapy for Type 1 diabetes that caused fanfare when he detailed its potential in October has received $44 million of Series A funding. Semma Therapeutics announced today the money will help it bring the potential drug through proof-of-concept in humans.
Des scientifiques de l'Université de Colombie Britannique (UBC) et BetaLogics, de Janssen Research & Development, LLC, ont montré pour la première fois que le diabète de type 2 peut être traité efficacement par une combinaison de cellules souches spécialement cultivées et de médicaments contre les diabètes classiques.
Several studies have already linked the likelihood of death by respiratory and circulatory illness to the level of fine dust particles in the air. A Munich study now shows that high levels of fine dust pollution could increase the risk of type 1 diabetes among children. EurActiv Germany reports.
For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.”
Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same management (focused on commercializing a dietary ingredient called Lovidia), the company has crossed off a variety of accomplishments that include:
—Selling NaZura BioHealth about a year ago in a deal that has not been previously disclosed. Elcelyx CEO Alain Baron said Elcelyx pocketed some proceeds from the sale, although he declined to provide details.
Patients whose diabetes has progressed to a type of kidney damage called diabetic nephropathy have few treatment options available to them. Some doctors treat the condition with blood pressure medication. But there are no FDA-approved drugs to specifically treat diabetic nephropathy, which can lead to end-stage renal failure. At that stage, patients will likely need dialysis or even a kidney transplant.
Research Triangle Park, NC-based Vascular Pharmaceuticals has developed a drug that, if all goes well, could become the first diabetic nephropathy drug. For now, the company is still trying to prove the concept.
Les scientifiques de l'université de Maynooth ont identifié une protéine du corps humain qui pourrait empêcher le développement du diabète de type 2, le diabète lié à l'obésité.
Fourteen years ago, during the darkest moments of the “stem-cell wars” pitting American scientists against the White House of George W. Bush, one group of advocates could be counted on to urge research using cells from human embryos: parents of children with type 1 diabetes. Motivated by scientists who told them these cells would lead to amazing cures, they spent millions on TV ads, lobbying, and countless phone calls to Congress.
Fourteen years ago, during the darkest moments of the “stem-cell wars” pitting American scientists against the White House of George W. Bush, one group of advocates could be counted on to urge research using cells from human embryos: parents of children with type 1 diabetes. Motivated by scientists who told them these cells would lead to amazing cures, they spent millions on TV ads, lobbying, and countless phone calls to Congress.
Diabetics engage in a painful ritual every day, often several times: pricking their fingers with a spring-loaded needle to test the glucose in their blood. But that ritual could soon be put to rest, and replaced by a small patch designed to extract and measure blood-sugar levels. Flexible, easy to apply, and inconspicuous, the next-generation wearable is a promising step toward noninvasive monitoring of diabetes, a disease that affects 29.1 million people in the U.S., according to the Centers for Disease Control [PDF].
